Home > Insider Trading > Filing (0001140361-14-044255)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1184149	W Jonathan Ayers	One Idexx Drive Westbrook ME 04092	Chairman, President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-12-03	29,000	$28.66	445,081	No	4	M	Direct
Common Stock	Disposition	2014-12-03	10,958	$148.12	434,123	No	4	S	Direct
Common Stock	Disposition	2014-12-03	18,042	$148.72	416,081	No	4	S	Direct
Common Stock	Acquisiton	2014-12-04	15,000	$34.37	431,081	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2014-12-03	29,000	$0.00	29,000	$28.66
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2014-12-04	15,000	$0.00	15,000	$34.37

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
28,512		2015-02-02	No	4	M	Direct
52,089		2016-02-13	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	49,000	Indirect	By Ayers Family Trust

Footnotes

The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2014.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $147.49 to $148.48, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $148.49 to $149.00, inclusive.
Grant of options to buy shares of common stock that became exercisable as to 20,000 shares on 02/03/2006, 02/03/2007, 02/03/2008 and 02/03/2009, and the remaining 16,512 shares on 02/03/2010.
Grant of options to buy shares of common stock that became exercisable as to 15,999 shares on 02/14/2010 and 02/14/2013, 16,000 shares on 02/14/2011 and 02/14/2012, and the remaining 13,091 shares on 02/14/2014.